LUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24

LUCID CAPITAL MARKETS has initiated coverage on Turn Therapeutics (NASDAQ: TTRX) with a Buy rating. The firm has set a price target of $24 for the stock.